Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster of H5N1 Pandemic Vaccine (GSK1562902A) in Adults
NCT00506350Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2007
- Primary completion
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Adjupanrix (9 arms), sponsored by GSK. Primary endpoints: Titers for Serum H5N1 Haemagglutinin Inhibition (HI) Antibodies Against the A/Indonesia/05/2005 Strain at Day 21, Number of Seroconverted Subjects for H5N1 HI Antibodies Against the A/Indonesia/05/2005 Strain at Day 21 and 6 more. Started Aug 2007; status: completed.
02
Drugs
Adjupanrix
Beyond the preview
Go deeper on NCT00506350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506350.